C
Carvolix
The new generation of minimally invasive implants to treat diseases of the heart, aorta, and urinary incontinence
About Carvolix
Affluent Medical, established in Aix-en-Provence, France, is a medical technology company focusing on the development of minimally invasive implants for the cardiovascular and urology sectors. Founded in 2011 by Michel Finance and Léopold Séguéla through the merger of four startups (Epygon, Kalios, Kardiozis, and Artus), the firm aims to address significant unmet medical needs in these fields. Michel Finance, serving as CEO, brings extensive experience from the medical device industry, having held leadership roles at companies like Sorin Group and St. Jude Medical. Co-founder Léopold Séguéla is a cardiac surgeon, providing deep clinical and anatomical expertise that directly informs the company's product development.
The company's business model centers on developing and bringing to market a portfolio of advanced medical devices. Affluent Medical generates revenue through the sale of these products once they receive regulatory approval and are commercialized. Its target clients are hospitals and surgical centers, with the ultimate beneficiaries being patients suffering from specific cardiovascular and urological conditions. The company operates in the global medical device market, with an initial focus on Europe. A significant milestone was its initial public offering (IPO) on the Euronext Paris exchange in 2021, which was intended to finance the clinical development of its key products.
Affluent Medical's product pipeline includes several devices currently in clinical or preclinical stages. For mitral valve disease, the company is developing Epygon, a transcatheter mitral valve designed to mimic the heart's natural blood flow, and Kalios, an adjustable ring for mitral valve repair that allows for non-invasive postoperative adjustments. In the vascular domain, Kardiozis is an implant designed to prevent endoleaks following abdominal aortic aneurysm repair. For urology, Artus is presented as the first electronically activated artificial urinary sphincter to treat stress urinary incontinence in both men and women.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2011
- Headquarters
- Paris, France
- Listing
- IPO 2021
- Employees
- 65
- Open positions
- None listed
- Dealroom signal
- 64.4/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, biotech medtech and e-health, Observatoire Deeptech, observatoire industrial tech, DT and LS, observatoire healthtech, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 2 companies, latest Dec 2025
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO CONVERTIBLE✓Other financing | Aug 2026 | $11M | — | Claret Capital Partners | ↗ |
| POST IPO EQUITY✓Other financing | Jun 2026 | $11M | — | Truffle Capital · Edwards Lifesciences | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Carvolix is 2.3K monthly website visits, down 23.3% over the last three months. Carvolix's team declined 5.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
ArtedroneParis, FranceProviding new tools to neurointerventional radiologists to address a significant unmet need with regards to smaller, more tortuous or more distal vessels, through safer procedures
$2.2Mvaluation
Caranx MedicalParis, FrancePrecision-crafted solutions for modern healthcare
→
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Truffle Capital
Claret Capital Partners
Series B and later1 investor entered at this stage
Edwards Lifesciences
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Carvolix on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Carvolix’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.